Actively Recruiting
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Led by Anna Stanhewicz, PhD · Updated on 2025-05-13
30
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
CONDITIONS
Official Title
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 12 weeks and no more than 45 years postpartum
- History of gestational diabetes mellitus (GDM) or healthy pregnancy
You will not qualify if you...
- Prediabetes or diabetes with HbA1c 5.7% or higher
- Current tobacco use
- Cardiovascular or metabolic disease
- Taking cardiovascular or metabolic medication
- History of high blood pressure during pregnancy
- Currently pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
Research Team
A
Anna Stanhewicz, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here